Denosumab Prolia Listing Extended To Include Men Over 70 Years With Osteoporosis. The drug was also more effective in improving bmd than bisphosphonates, including in women denosumab was generally well tolerated over up to 10 years' treatment. You may report side effects.
Are at risk for poor outcomes, including fractures.
Prevalence in men in recent years. (1) the studied population had to include patients of any age with osteoporosis; Over 12 months, denosumab did not accumulate appreciably at any of the dosage frequencies that were investigated, and its pharmacokinetics did not change substantially after multiple doses. Pharmacology, pharmacokinetics, contraindications, interactions and adverse reactions.
Post a Comment for "Denosumab Prolia Listing Extended To Include Men Over 70 Years With Osteoporosis"